PLX108-08: An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

8214-CTO
Cancer - Brain
Principal Investigator: Tommy Mikkelsen, MD

The study objectives are to assess the potential for PLX3397 to improve the efficacy of standard of care radiation therapy (RT) + temozolomide in patients with newly diagnosed glioblastoma (GBM).

  • Male or female patients =18 years old.
  • Histologically confirmed definitive GBM or gliosarcoma by partial or complete surgical resection (i.e. not by biopsy only) within 5 weeks prior to PLX3397 administration (C1D1). Tumor must have a supratentorial component.
  • The patient must have recovered from the effects of surgery, post-operative infection, and other complications before study registration.

Please contact us for a full list of eligibility criteria.

Open
Tiffany Pearce
313-916-1784